K
Karyopharm Therapeutics Inc. (KPTI)
NMS – Real vaqt narxi. Valyuta: USD
8.91
+0.10 (1.19%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
8.91
+0.10 (1.19%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Karyopharm Therapeutics Inc., tijorat bosqichidagi farmatsevtika kompaniyasi, Qo'shma Shtatlarda saraton va boshqa kasalliklarni davolash uchun yadroviy eksportga qarshi dorilarni kashf qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya yadroviy eksport oqsilini eksportin 1 (XPO1) ingibitsiya qiluvchi yangi va kichik molekulali tanlovli yadroviy eksport ingibitorlari (SINE) birikmalarini kashf qiladi, ishlab chiqadi va tijoratlashtiradi. Uning asosiy birikmalariga ko'p miyeloma bilan og'rigan kattalar bemorlarini davolash uchun bortezomib va deksametazon bilan birgalikda XPOVIO; qaytalangan yoki refrakter ko'p miyeloma bilan og'rigan kattalar bemorlarini davolash uchun deksametazon bilan birgalikda; hamda qaytalangan yoki refrakter diffuz katta B-hujayrali limfoma (DLBCL) bilan og'rigan kattalar bemorlarini davolash uchun kiradi. Kompaniya, shuningdek, ko'p miyeloma, endometriy saratoni, mielofibroz va DLBCLni o'z ichiga olgan gematologik va qattiq o'simtalarni davolash uchun Selinexor; hamda boshqa mieloproliferativ neoplazmalar va TP53 yovvoyi tipdagi qattiq o'simtalarni davolash uchun ELTANEXORni ishlab chiqadi. Bundan tashqari, kompaniya inson onkologik ko'rsatmalari uchun selinexor ishlab chiqish va tijoratlashtirish bo'yicha Menarini Group bilan litsenziya shartnomasiga ega; inson onkologik ko'rsatmalari uchun selinexor, eltanexor va KPT-9274 ishlab chiqish va tijoratlashtirish, shuningdek, inson onkologik bo'lmagan ko'rsatmalarni tashxislash, davolash va/yoki oldini olish uchun verdinexor bo'yicha Antengene Therapeutics Limited bilan litsenziya shartnomasiga ega; hamda FORUS Therapeutics Inc. bilan XPOVIO tijoratlashtirish bo'yicha distribyutorlik shartnomasiga ega. Bundan tashqari, kompaniya qaytalangan yoki refrakter ko'p miyelomali bemorlarda Selinexor bilan birgalikda yangi sereblon E3 ligaza modulyatori agenti mezigdomide baholash uchun Bristol Myers Squibb kompaniyasi bilan hamkorlik qiladi. Karyopharm Therapeutics Inc. 2008 yilda tashkil etilgan va shtab-kvartirasi Nyu-ton, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Reshma Rangwala M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Research |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Mr. Brendan Twohig Strong | Senior Vice President of Investor Relations |
| Mr. James Accumanno J.D. | Chief Compliance Officer |
| Mr. Michael J. Mano J.D. | Executive VP, Chief Legal Officer & Secretary |
| Mr. Richard A. Paulson M.B.A. | President, CEO & Director |
| Mr. Stuart Poulton | Executive VP & Chief Development Officer |
| Ms. Kristin Abate | VP, Chief Accounting Officer & Assistant Treasurer |
| Ms. Lisa DiPaolo | Executive VP & Chief Human Resource Officer |
| Ms. Lori A. Macomber CPA | EVP, CFO & Treasurer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-04 | S-3 | d69189ds3.htm |
| 2026-04-13 | DEF 14A | kpti-20260413.htm |
| 2026-04-13 | ARS | kpti_ars_2026.pdf |
| 2026-03-27 | 8-K | kpti-20260327.htm |
| 2026-03-24 | 8-K | d125009d8k.htm |
| 2026-03-03 | 8-K | kpti-20260227.htm |
| 2026-02-19 | 8-K | kpti-20260218.htm |
| 2026-02-13 | 10-K | kpti-20251231.htm |
| 2026-02-12 | 8-K | kpti-20260212.htm |
| 2026-01-12 | 8-K | kpti-20260112.htm |